Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies

NCT07249905 is registered in ClinicalTrials.gov with ModeX Therapeutics, An OPKO Health Company as lead sponsor.

NCT NCT07249905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07249905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies
Lead sponsor
ModeX Therapeutics, An OPKO Health Company
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 13, 2026
Completion date
April 30, 2030
Enrollment
180 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl - diffuse large b cell lymphoma, fl lymphoma, follicular lymphoma (fl), hgbcl, lymphoma, lymphoplasmacytic lymphoma, pmbcl, waldenström macroglobulinemia (wm)